BR112022006643A2 - Formulações de liberação controlada de substâncias fisiologicamente ativas altamente lipofílicas - Google Patents

Formulações de liberação controlada de substâncias fisiologicamente ativas altamente lipofílicas

Info

Publication number
BR112022006643A2
BR112022006643A2 BR112022006643A BR112022006643A BR112022006643A2 BR 112022006643 A2 BR112022006643 A2 BR 112022006643A2 BR 112022006643 A BR112022006643 A BR 112022006643A BR 112022006643 A BR112022006643 A BR 112022006643A BR 112022006643 A2 BR112022006643 A2 BR 112022006643A2
Authority
BR
Brazil
Prior art keywords
active substances
physiologically active
controlled release
release formulations
highly lipophilic
Prior art date
Application number
BR112022006643A
Other languages
English (en)
Portuguese (pt)
Inventor
Nowak Mirko
Jesko Nowak Jay
Grave Annette
Wentzlaff Monika
Barthold Sarah
Geugelin Christian
Original Assignee
Add Advanced Drug Delivery Tech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Add Advanced Drug Delivery Tech Ltd filed Critical Add Advanced Drug Delivery Tech Ltd
Publication of BR112022006643A2 publication Critical patent/BR112022006643A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2813—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112022006643A 2019-10-16 2020-10-16 Formulações de liberação controlada de substâncias fisiologicamente ativas altamente lipofílicas BR112022006643A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19203580.6A EP3808341A1 (de) 2019-10-16 2019-10-16 Kontrolliert freisetzende formulierungen stark lipophiler physiologisch aktiver substanzen
PCT/EP2020/079248 WO2021074403A1 (de) 2019-10-16 2020-10-16 Kontrolliert freisetzende formulierungen stark lipophiler physiologisch aktiver substanzen

Publications (1)

Publication Number Publication Date
BR112022006643A2 true BR112022006643A2 (pt) 2022-07-12

Family

ID=68281185

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022006643A BR112022006643A2 (pt) 2019-10-16 2020-10-16 Formulações de liberação controlada de substâncias fisiologicamente ativas altamente lipofílicas

Country Status (10)

Country Link
US (1) US20240139215A1 (https=)
EP (2) EP3808341A1 (https=)
JP (2) JP7778069B2 (https=)
CN (1) CN114945353A (https=)
AU (1) AU2020365443A1 (https=)
BR (1) BR112022006643A2 (https=)
CA (1) CA3157654A1 (https=)
IL (1) IL292018A (https=)
MX (1) MX2022004523A (https=)
WO (1) WO2021074403A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3808336A1 (de) * 2019-10-16 2021-04-21 ADD Advanced Drug Delivery Technologies, Ltd. Kontrolliert freisetzende formulierungen stark lipophiler physiologisch aktiver substanzen
CA3205594A1 (en) 2020-12-17 2022-06-23 Nalu Bio, Inc. Synthesis of cannabidiol and analogs thereof, and related compounds, formulations, and methods of use
GB2618322A (en) * 2022-04-29 2023-11-08 113 Botanicals Ltd Compositions and methods

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1361864T3 (en) * 2001-02-14 2014-03-03 Gw Pharma Ltd FLYLDENDE SPRAY FORMULATIONS FOR buccal administration of cannabinoids
EP1364646A4 (en) 2001-03-01 2005-08-03 Grelan Pharmaceutical Co FENOFIBRATE CONTAINING COMPOSITION
DE10226494A1 (de) * 2002-06-14 2004-01-08 Lts Lohmann Therapie-Systeme Ag Filmförmige mucoadhäsive Darreichungsformen zur Verabreichung von Cannabis-Wirkstoffen
WO2008024490A2 (en) 2006-08-24 2008-02-28 Theraquest Biosciences, Inc. Oral pharmaceutical formulations of abuse deterrent cannabinoids and method of use
CA2929321C (en) 2013-10-29 2022-04-05 Echo Pharmaceuticals B.V. Compressed tablet containing cannabidiol, method for its manufacture and use of such tablet in oral treatment of psychosis or anxiety disorders
DE102014213548A1 (de) * 2014-07-11 2016-01-14 Hans Brammer Cannabispräparat
RS67855B1 (sr) * 2014-08-11 2026-03-31 Woerwag Pharma Gmbh & Co Kg Formulacija koja sadrži čestice
IL246790A0 (en) 2016-07-14 2016-09-29 Friedman Doron Self-dissolving compounds of cannabinoids
WO2018035030A1 (en) 2016-08-15 2018-02-22 Corr-Jensen Inc. Time release fat-soluble actives
JP2019137614A (ja) 2018-02-06 2019-08-22 富士フイルム株式会社 経口用医薬組成物及びその製造方法
DE102019100483A1 (de) * 2019-01-10 2020-07-16 Lts Lohmann Therapie-Systeme Ag Oraler Dünnfilm

Also Published As

Publication number Publication date
EP3808341A1 (de) 2021-04-21
EP4045014A1 (de) 2022-08-24
JP2022553653A (ja) 2022-12-26
IL292018A (en) 2022-06-01
JP7778069B2 (ja) 2025-12-01
JP2025182116A (ja) 2025-12-11
AU2020365443A1 (en) 2022-06-02
US20240139215A1 (en) 2024-05-02
WO2021074403A1 (de) 2021-04-22
MX2022004523A (es) 2022-09-19
CA3157654A1 (en) 2021-04-22
CN114945353A (zh) 2022-08-26

Similar Documents

Publication Publication Date Title
BR112022024943A2 (pt) Composição oral efervescente compreendendo um ingrediente ativo
MX2020006957A (es) Composicion de liberacion modificada que comprende un cannabinoide.
BR112022010894A2 (pt) Composições orais úmidas
BR112022006643A2 (pt) Formulações de liberação controlada de substâncias fisiologicamente ativas altamente lipofílicas
MA46990B1 (fr) Compositions glp-1 et ses utilisations
CY1126152T1 (el) Ενωσεις-αναστολεις της rip1 και μεθοδοι παρασκευης και χρησης αυτων
BR112018006259A2 (pt) "adjunto compressível com estruturas de suporte intermediárias"
BR112015026549A2 (pt) forma de dosagem à prova de violação contendo uma ou mais partículas
BR112019007798A2 (pt) veículo de liberação oral
MX2022005509A (es) Compuestos inhibidores de rip1 heterociclicos.
BR112017024517A2 (pt) compostos de tetraidroquinolinona como moduladores ror gama
EA201792345A1 (ru) Защищенная от применения не по назначению лекарственная форма с немедленным высвобождением и устойчивостью к экстракции растворителями
BR112019001923A2 (pt) moduladores de nmda de espiro-lactama e métodos de sua utilização
BR112018006368A2 (pt) composição para desempenho melhorado
BR112015024271A2 (pt) sistema de fornecimento transdérmico
ECSP22040921A (es) Composición farmacéutica que comprende selexipag
BR112017006180A2 (pt) composições de redução de mau odor
CR20230259A (es) Anticuerpos de cadena pesada que se unen al receptor de folato alfa
FR3058059B1 (fr) Composition pharmaceutique comprenant le beta-elemene, le lupeol et le 2-hydroxycinnamaldehyde et/ou le 2'-benzoyloxycinnalmaldehyde et/ou le beta-sitosterol et/ou la curcumine.
CL2020002101A1 (es) Formulaciones de liberación sostenida de ácido bempedoico.
SA520420261B1 (ar) تركيبات إرنوماب واستخداماتها
BR112019001207A2 (pt) composição vaginal compreendendo uma combinação de estrogênio e vitamina d
ECSP10010683A (es) Una formulacion farmacéutica sólida
BR112017016794A2 (pt) microcápsulas que conferem nota de odor intenso de baunilha
BR112022010872A2 (pt) Produtos orais

Legal Events

Date Code Title Description
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]